Grant of Options and PDMR Dealing

RNS Number : 4292F

Oncimmune Holdings PLC

04 November 2022

 

4 November 2022

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Grant of Options and PDMR Dealing

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that on 3 November 2022, options ("Options") to subscribe for an aggregate of 196,809 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted to Adam Hill (Chief Executive Officer), Matthew Hall (Chief Financial Officer) and Ron Kirschner (General Counsel & Company Secretary) as follows:

Name	Position	No. of Options Awarded	Exercise Price per Share
Adam Hill	Chief Executive Officer	125,000	£0.50
Matthew Hall	Chief Financial Officer	30,000	£0.50
Ron Kirschner	General Counsel & Company Secretary	30,000	£0.50

The Options have been granted under the 2016 Share Option Plan, have an exercise price of £0.50, being the closing price of Ordinary Shares in Oncimmune Holdings plc on 2 November 2022, and vest annually in five equal parts from the date of grant until the fifth anniversary of grant.  

Following this grant, each of Adam Hill, Matthew Hall and Ron Kirschner hold the following interests in the Company:

Name	Number of Ordinary Shares currently held	Number of Options held post grant
Adam Hill	73,872	3,615,862
Matthew Hall	11,935	809,554
Ron Kirschner	1,652	556,738

This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation and serves as notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	1.  Adam Hill 2.  Matthew Hall 3.  Ron Kirschner
2	Reason for the notification
a)	Position/status	1.  Chief Executive Officer 2.  Chief Financial Officer 3.  General Counsel & Company Secretary
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oncimmune Holdings plc
b)	LEI	213800HCYIWT6YPI1I02
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	ISIN: GB00BYQ94H38
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1. £0.50	125,000
			2. £0.50	30,000
			3. £0.50	30,000
d)	Aggregated information
	- Aggregated volume	N/A - single transaction
	- Price
e)	Date of the transaction	3 November 2022
f)	Place of the transaction	Outside a trading venue

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

[phone]

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

[phone]

Media enquiries:

Freelands Finance

John Goold

[e-mail]

 

END

 

 

DSHBKQBDABDDNDK